Amneal Pharmaceuticals, Inc. (AMRX)
11.87
-0.31
(-2.55%)
USD |
NASDAQ |
Dec 08, 15:56
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 3.731B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 41.14% |
| Valuation | |
| PE Ratio | 841.84 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.295 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -24.54 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 94.77% |
Profile
| Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ. |
| URL | http://www.amneal.com |
| Investor Relations URL | https://investors.amneal.com/investor-relations/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 27, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ. |
| URL | http://www.amneal.com |
| Investor Relations URL | https://investors.amneal.com/investor-relations/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 27, 2026 (est.) |
| Last Earnings Release | Oct. 30, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |